Alembic Pharmaceuticals Limited Announces Unaudited Consolidated and Standalone Earnings Results for the Third Quarter and Nine Months Ended December 31, 2016
January 25, 2017 at 02:44 am
Share
Alembic Pharmaceuticals Limited announced unaudited consolidated and standalone earnings results for the third quarter and nine months ended December 31, 2016. For the quarter, on consolidated basis, the company's net sales/income from operations was INR 7,761.5 million compared with INR 9,301.7 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 1,242.8 million compared with INR 3,623.3 million a year ago. Profit from ordinary activities before tax was INR 1,236.8 million compared with INR 3,640.9 million a year ago. Net profit after tax was INR 865.5 million or INR 4.59 per basic and diluted share compared with INR 2,688.7 million or INR 14.26 per basic and diluted share a year ago.
For the nine months, on consolidated basis, the company's net sales/income from operations was INR 23,906.7 million compared with INR 25,368.4 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 4,190.0 million compared with INR 8,162.3 million a year ago. Profit from ordinary activities before tax was INR 4,172.7 million compared with INR 8,167.4 million a year ago. Net profit after tax was INR 3,101.2 million or INR 16.45 per basic and diluted share compared with INR 6,296.2 million or INR 33.40 per basic and diluted share a year ago.
For the quarter, on standalone basis, the company's net sales/income from operations was INR 8,039.3 million compared with INR 9,061.3 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 1,741.2 million compared with INR 3,720.2 million a year ago. Profit from ordinary activities before tax was INR 1,740.5 million compared with INR 3,741.5 million a year ago. Net profit after tax was INR 1,378.3 million or INR 7.31 per basic and diluted share compared with INR 2,789.2 million or INR 14.80 per basic and diluted share a year ago.
For the nine months, on standalone basis, the company's net sales/income from operations was INR 23,363.2 million compared with INR 24,181.1 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 4,736.6 million compared with INR 7,961.0 million a year ago. Profit from ordinary activities before tax was INR 4,734.0 million compared with INR 7,974.3 million a year ago. Net profit after tax was INR 3,714.0 million or INR 19.70 per basic and diluted share compared with INR 6,093.6 million or INR 32.32 per basic and diluted share a year ago.
Alembic Pharmaceuticals Limited is an India-based pharmaceutical company. The Company is involved in manufacturing and marketing India Formulations, International Generics, and Active Pharmaceutical Ingredients (API). It delivers a diverse and expanding range of generics across chronic segments. Its therapies include Dermatology, Anti-Infective, Cold & Cough, Gastrology, Cardiology, Anti-Diabetic, Ophthalmology, Nephro/Uro, Animal Health, Orthopaedic and Gynaecology. Products under International Generics are manufactured across its facilities in Panelav, Karkhadi and Jarod in Gujarat. It has research and development facilities in Vadodara (Gujarat), Hyderabad (Telangana), and New Jersey (United States). Its APIs are manufactured at its three plants in Panelav and Karkhadi in Gujarat. The manufacturing facility in Sikkim is for manufacturing its India Formulations. Its subsidiaries include Alembic Pharmaceuticals Inc., Alembic Global Holding SA and others.
Alembic Pharmaceuticals Limited Announces Unaudited Consolidated and Standalone Earnings Results for the Third Quarter and Nine Months Ended December 31, 2016